Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYK-491 ascending-dose safety study in stable HFrEF
NL-OMON48219Phase 2Active, not recruiting
- Sponsor
- MyoKardia
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of danicamtiv in heart failure with reduced ejection fraction (HFrEF) and dilated cardiomyopathy (DCM) (6 arms), sponsored by MyoKardia. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Electrocardiogram assessments and 4 more. Started Aug 2019; status: active, not recruiting.
02
Drugs
danicamtiv
03
Conditions
heart failure with reduced ejection fraction (HFrEF)dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NL-OMON48219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48219.